Thymosin β4

Cited range Parent peptide

ClassG-actin sequestering peptide

Typical routes in papersSC, sometimes topical in research

Half-life contextHours-range in descriptions

EvidenceHuman injury / ocular research plus animal repair models

What it is

Thymosin β4 is the natural protein TB-500 is trying to stand in for. It helps cells move, grow new micro-vessels, and calm some inflammatory mess after injury.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

Same family benefits as TB-500: mobility of repair cells, flexibility talk, wound and eye-surface research.
The full sequence is what hospitals and trials mean when they say TB4 — not every research vial labeled TB-500.
Think repair and cell traffic, not a pump.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

Sequesters G-actin, frees cells to migrate; also peptides-out fragments (including Ac-SDKP) with anti-fibrotic and angiogenic themes.

Possible side effects / caveats

Theoretical angiogenic caution, injection reactions, and label confusion with TB-500 fragments of unknown length.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Cited range	2–5 mg/week	Loading then step-down, mirroring TB-500 notes	Community parallel
Trial / clinical literature	Protocol-specific	Ocular and wound programs	Do not copy a trial into a research vial

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.